Todd E. Rambasek, MD

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kavurum@ccf.org

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kavurum@ccf.org

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kavurum@ccf.org

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.